Sympathetic activation in chronic renal failure.

  title={Sympathetic activation in chronic renal failure.},
  author={Markus P. Schlaich and Flora Socratous and Sarah C. Hennebry and Nina Eikelis and Elisabeth A. Lambert and Nora E. Straznicky and Murray D Esler and Gavin W. Lambert},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={20 5},
The potential involvement of sympathetic overactivity has been neglected in this population despite accumulating experimental and clinical evidence suggesting a crucial role of sympathetic activation for both progression of renal failure and the high rate of cardiovascular events in patients with chronic kidney disease. The contribution of sympathetic neural mechanisms to the occurrence of cardiac arrhythmias, the development of hypertension, and the progression of heart failure are well… 

Figures from this paper

The Sympathetic Nervous System in Chronic Kidney Disease

Current knowledge of the role of the sympathetic nervous system in the development and progression of CKD will be summarized, and novel treatment options targeting sympathetic nervousSystem activity will be discussed.

[Sympathetic nerve activity in chronic renal failure - what are the therapeutic options?].

Therapeutic options for hypertensive patients with chronic renal failure with respect to their sympathetic overactivity are inhibitors of the renin-angiotensin-system and central sympatholytic drugs.

Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.

  • D. HeringM. EslerM. Schlaich
  • Medicine, Biology
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2013
Preliminary data to suggest that this approach can also be applied safely in patients with stage 3-4 CKD, and if appropriately designed clinical trials can confirm these initial observations, renal denervation may become a valuable new treatment option for the large cohort of patients with CKD.

Sympathetic nervous system: role in hypertension and in chronic kidney disease

Recent findings indicate that the metabolic disarray frequently complicating the high blood pressure state (metabolic syndrome, dislipidemia, insulin resistance) may have as pathophysiological background a sympathetic overdrive.

Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation?

The potential importance of RDN for patients with chronic kidney disease (CKD) is discussed, and the role of the kidneys as both generators and recipients of sympathetic hyperactivity is described.

Renal Denervation: Potential Future Implications Beyond Resistant Hypertension

Preliminary data obtained from small and mostly uncontrolled studies in related disease states often characterised by over-activity of the SNS are promising but require confirmation in appropriately designed clinical trials.

The Role of Renal Denervation in the Treatment of Heart Failure

A novel catheter-based device has recently been introduced that specifically interrupts both efferent and afferent renal nerves, and there is significant interest in the use of this device to treat both hypertension and CHF.

The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease

  • Y. SataM. Schlaich
  • Medicine, Biology
    Journal of cardiovascular pharmacology and therapeutics
  • 2016
The potential role of catheter-based renal denervation in patients with impaired kidney function is discussed and the potential impact on other cardiovascular conditions commonly associated with chronic kidney disease such as heart failure and arrhythmias is reflected.

Sympathetic Activation in Hypertensive Chronic Kidney Disease – A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?

The role of the feedback loop of the sympathetic neural cycle in the context of CKD and how it may aggravate several of the risk factors responsible for causing SCD is revisited.

Cardiovascular Disease in Chronic Kidney Disease

  • M. SarnakD. Weiner
  • Medicine, Biology
    Chronic Kidney Disease, Dialysis, and Transplantation
  • 2019



Sympathetic hyperactivity in chronic renal failure: a wake-up call.

A case is made for increased application of specific adrenergic blockers in patients with CRF, because of the unwillingness to treat CRF patients with beta-blockers, even if they have had a myocardial infarction.

Sympathetic overactivity in patients with chronic renal failure.

Chronic renal failure may be accompanied by reversible sympathetic activation, which appears to be mediated by an afferent signal arising in the failing kidneys.

Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.

Increased sympathetic activity contributes to hypertension in patients with chronic renal disease and controls hypertension and decreases sympathetic hyperactivity.

Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure

Tonic activation of excitatory chemoreflex afferents contributes to increased efferent sympathetic activity to muscle circulation and to blood pressure control in patients with CRF, and may have important implications for understanding mechanisms underlying the link between CRF and cardiovascular disease.

Neurogenic factors and hypertension in chronic renal failure.

  • V. Campese
  • Medicine, Biology
    Journal of nephrology
  • 1997
Dorsal rhizotomy prevented the development of hypertension in rats with chronic renal failure and showed greater norepinephrine turnover rate in the posterior hypothalamic nuclei and locus coeruleus of CRF than control rats.

Effect of chronic renal failure on nitric oxide metabolism.

  • N. Vaziri
  • Biology, Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2001
The purpose of this review is to provide a brief overview of the effect of CRF on the bioavailability of NO substrate, L-arginine; the expression of NOS isoforms in the relevant organs; the interaction of NO with reactive oxygen species that are known to be increased in CRF, and the accumulation of uremic inhibitors of N OS.

Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension.

It is indicated that MSNA is increased in hypertensive PKD patients regardless of renal function, and the data support the idea that sympathetic hyperactivity contributes to the pathogenesis of hypertension in PKD.

Sympathetic Nerve Activity in End-Stage Renal Disease

Increased SNA is observed in renal transplant recipients with diseased native kidneys at a level not significantly different from chronic hemodialysis patients, and seems to be mediated by signals arising in the native kidneys that are independent of circulating uremia related toxins.

Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease

Sympathetic nerve overactivity is associated with mortality and cardiovascular outcomes in ESRD and controlled trials with antiadrenergic drugs are needed to determine whether interference with the sympathetic system could reduce the high cardiovascular morbidity and mortality in dialysis patients.

Increased norepinephrine secretion in patients with the nephrotic syndrome and normal glomerular filtration rates: evidence for primary sympathetic activation.

Plasma renin activity and plasma aldosterone, arginine vasopressin and atrial natriuretic peptide concentrations were not different in nephrotic syndrome patients compared with controls, and the supine plasma norepinephrine level was elevated.